Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for an oversubscribed private placement expected to raise approximately $30 million in gross proceeds through pre-funded warrants and common stock warrants for up to about 37.2 million shares each. The warrants are priced at a purchase price of $0.808 per pre-funded warrant, with a common warrant exercise price of $0.683 per share. Aprea plans to use the upfront net proceeds for general corporate purposes and research and development and currently expects this funding to extend its cash runway into the first quarter of 2028. The company also reported a confirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer, along with additional stable disease cases, supporting early signs of anti-tumor activity.
Aprea Therapeutics is registering for resale 12,577,714 shares of Common Stock to permit selling stockholders to resell shares issued in a January 2026 private placement.
The registration covers (i) 1,877,677 shares issued in the Private Placement, (ii) 4,411,180 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.001, and (iii) 6,288,857 shares issuable upon exercise of common warrants at an exercise price of $0.765. The company will receive no proceeds from resale transactions, but will receive cash if warrants are exercised for cash.
Shares outstanding were 11,451,118 as of January 30, 2026. The prospectus discloses a Nasdaq listing under the symbol APRE and a March 18, 2026 last reported sale price of $0.7311.
Aprea Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (File No. 333-293609) to furnish an updated consent of EisnerAmper LLP (Exhibit 23.2). The amendment states it does not modify any provision of the prospectus and is limited to filing the updated consent.
The amendment delays effectiveness mechanics remain unchanged and the registrant reiterates customary undertakings and exhibits, including legal opinion of DLA Piper and previously incorporated offering documents.
Aprea Therapeutics president and CEO Gilad Oren reported new equity awards. He received stock options for 80,700 shares of common stock at an exercise price of $0.765 per share, expiring on March 12, 2036. These options vest 25% on March 12, 2027, with the remainder vesting ratably over the following 36 months, subject to continued employment.
Oren was also granted 20,175 restricted stock units that vest in three equal annual installments beginning on March 12, 2027, also subject to continued employment. Following these grants, he directly holds 393,895 shares of common stock. Additional indirect holdings of 1,200 and 600 shares are reported for his daughter and son, with beneficial ownership disclaimed.
Aprea Therapeutics reported that SrVP/CFO/Principal Financial and Accounting Officer John P. Hamill received new equity compensation. He was granted 40,380 stock options with an exercise price of $0.765 per share, expiring on March 12, 2036.
Twenty-five percent of these options vest on March 12, 2027, with the remainder vesting monthly over the following 36 months, contingent on continued employment. Hamill also received 10,095 restricted stock units, vesting in three equal annual installments starting March 12, 2027. Following the RSU grant, his common stock holdings total 43,528 shares.
Aprea Therapeutics, Inc. reported 2025 results and clinical progress in its oncology pipeline. In the Phase 1 APR-1051 study, two patients with PPP2R1A-mutated endometrial cancers had preliminary, unconfirmed partial responses, each with a 50% target-lesion reduction at first imaging, at 150 mg and 220 mg. As of March 2, 2026, enrollment was in cohort 8 at 220 mg once daily.
Aprea determined ATRN-119’s recommended Phase 2 dose at 1,100 mg once daily. It paused further enrollment in both once- and twice-daily monotherapy arms and began an orderly wind-down of certain trial-site activities while exploring combination approaches.
2025 grant revenue was $285,759, versus $1,502,581 in 2024; research and development expense was $7,043,035 and net loss was $12,599,569. Cash and cash equivalents were $14.6 million as of December 31, 2025, and the January 2026 private placement generated approximately $5.6 million gross. The MD&A estimates resources would fund projected expenses into the first quarter of 2027, while Note 1 says they will not cover needs through at least 12 months from issuance; Aprea concluded substantial doubt exists about its ability to continue as a going concern and is seeking additional equity financing.
Aprea Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided a corporate update. For 2025, grant revenue was $285,759, down from $1,502,581 in 2024, reflecting lower non-dilutive funding.
Total operating expenses for 2025 were $13,519,595, compared with $15,822,236 in 2024, driven by lower research and development spending of $7,043,035 and relatively stable general and administrative costs of $6,476,560. Net loss for 2025 was $12,599,569, slightly improved from $12,958,711 in 2024, with net loss per share narrowing to $1.93 from $2.35.
On the balance sheet, total assets at December 31, 2025 were $15,933,401, down from $23,979,493 a year earlier, including cash and cash equivalents of $14,599,347. The company highlighted progress in its WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119 programs and noted recent private placements that strengthened its balance sheet, while emphasizing its focus on targeted therapies for biomarker-defined cancers.
Aprea Therapeutics registers 12,577,714 shares for resale by private placement investors. This registration covers up to 12,577,714 shares of Common Stock consisting of 1,877,677 shares issued in the January 30, 2026 private placement, 4,411,180 shares issuable upon exercise of pre-funded warrants, and 6,288,857 shares issuable upon exercise of common warrants.
The company is not offering any shares for its own account and will not receive proceeds from resales, although it will receive proceeds from any cash exercise of warrants. The filing discloses an exercise price of $0.765 for common warrants and $0.001 for pre-funded warrants, and states the company had 11,451,118 shares outstanding as of January 30, 2026. The last reported Nasdaq sale price was $0.8179 on February 19, 2026.
Aprea Therapeutics reported new early clinical signals for its WEE1 inhibitor APR-1051 from the ongoing Phase 1 ACESOT-1051 trial in advanced solid tumors. A second unconfirmed partial response was seen in a patient with advanced endometrial cancer at the 220 mg dose, showing a 50% reduction in target lesions and an 87% drop in CA-125, from 362 U/mL to 47 U/mL. The tumor carries a PPP2R1A mutation, and the patient has only experienced Grade 1 treatment-emergent side effects and remains on therapy. Across the study, 22 patients have been treated at doses from 10 mg to 220 mg, and a further trial update is planned for the second quarter of 2026.